Tectonic Therapeutic expects TX45 Phase II data by end of January and plans PHILD interim data in the second half of 2027, with cash runway through the first quarter of 2029.
TECX · Tectonic Therapeutic, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $21.04
- Open
- $21.01
- Day range
- $20.61–21.55
- 52-week closing range
- $17.93–37.93
- Average volume, 30 days
- 175K
- Short interest
- 2.4M · 11.9% of shares · 13.7 days
- Short volume, last session
- 68%
- Last earnings
- Feb 24, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Latest documents
Tectonic Therapeutic completed TX45’s APEX Phase 2 enrollment with 191 patients across 14 countries in June 2026 and expects topline results by the end of January 2027. The IDMC recommended continuing the study without modification.
Tectonic reported favorable TX2100 results, dosed the first patient in the TX45 ALPINE trial and expects APEX topline results by the end of January 2027. Cash of $234.7 million at September 30, 2026 supports runway into Q1 2029.
Tectonic Therapeutic reported favorable TX2100 Phase 1a safety and tolerability, with no deaths, serious adverse events or severe treatment-emergent adverse events. FDA granted Fast Track designation; Phase 1b and Phase 2 starts are planned by year-end 2026 and early 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TECX
this stock
Tectonic Therapeutic, Inc.
|
$419.71M | +0.9% | — | — | 11.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 11, 2026
- This year
- 16
Tectonic Therapeutic expects TX45 Phase II data by end of January and plans PHILD interim data in the second half of 2027, with cash runway through the first quarter of 2029.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TECX | +0.0% | -0.2% | -27.2% | +6.4% | +0.9% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +5.5% | +6.1% | -21.5% | +11.6% | -4.1% |